CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen

Journal of Immunology

Volumn 166, Issue 6, 2001, Pages 3908-3914

  Hernandez J ^a   Ko, A ^a   Sherman, L A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROTEIN P53; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXIC T LYMPHOCYTE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HELPER CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; T LYMPHOCYTE SUBPOPULATION;

EID: 0035869571     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.6.3908     Document Type: Article

References (41)

1. Cancer antigens: Immune recognition of self and altered self
2. Induction of anti-self-immunity to cure cancer
3. T cell defined tumor antigens
4. Strategies for tumor elimination by cytotoxic T lymphocytes
5. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
6. Tumor antigens are constitutively presented in the draining lymph nodes
7. + melanoma patients have a memory phenotype
8. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
9. CTLA-4 can function as a negative regulator of T cell activation
10. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
11. CTLA-4 ligation blocks CD28-dependent T cell activation
12. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
13. Enhancement of antitumor immunity by CTLA-4 blockade
14. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
15. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
16. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages
17. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
18. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice
19. + T cell help
20. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
21. + T cell- and IL-2-dependent mechanism
22. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
23. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
24. The p53 tumor suppressor gene
25. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes
26. p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos, and tumors
27. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb), and p53 during cell cycle progression of normal human T cells
28. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes
29. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self-tolerance on the TCR repertoire
30. Dissection of the B10.D2 anti-H-2Kb cytolytic T lymphocyte receptor repertoire
31. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8
32. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers
33. + T cells in the thymus
34. Activation of low avidity CTL specific for a self-epitope results in tumor rejection but not autoimmunity
35. + T cells
36. Antiviral CD4 and CD8 T-cell memory: Differences in the size of the response and activation requirements
37. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade: Heterogeneity within the human T-cell population
38. Epitope affinity for MHC class I determines helper requirement for CTL priming
39. + cytotoxic T lymphocytes
40. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
41. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy